Actively Recruiting
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
Led by Rush University Medical Center · Updated on 2025-09-22
100
Participants Needed
5
Research Sites
160 weeks
Total Duration
On this page
Sponsors
R
Rush University Medical Center
Lead Sponsor
U
University of Michigan
Collaborating Sponsor
AI-Summary
What this Trial Is About
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.
CONDITIONS
Official Title
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient 63; 18 years old
- Structural Heart Disease: Ischemic Cardiomyopathy
- Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation
You will not qualify if you...
- Clinical ventricular arrhythmia predominantly PVCs, supraventricular tachycardia, or ventricular fibrillation
- Myocardial infarction or cardiac surgery within 6 months
- Severe mitral regurgitation
- Stroke or TIA within 6 months
- Prior VT substrate ablation in the previous 6 months
- NYHA functional class IV
- Non-ischemic VT substrate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Rush University Medical Center
Chicago, Illinois, United States, 60614
Actively Recruiting
2
Mass General Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Not Yet Recruiting
3
Medical University of Michigan
Ann Arbor, Michigan, United States, 48109
Not Yet Recruiting
4
Mayo Clinic
Rochester, Minnesota, United States, 55905
Not Yet Recruiting
5
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Not Yet Recruiting
Research Team
A
Alexander Mazur, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here